当前位置: X-MOL 学术Clin. Med. Insights Oncol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Central Venous Catheter Thrombosis in Cancer: A Multi-Centre Retrospective Study Investigating Risk Factors and Contemporary Trends in Management.
Clinical Medicine Insights: Oncology ( IF 1.9 ) Pub Date : 2020-08-30 , DOI: 10.1177/1179554920953097
Lucy Haggstrom 1 , Gurdeep Parmar 2 , Daniel Brungs 1, 3
Affiliation  

Objectives:

Central venous access is needed to facilitate chemotherapy for many cancer patients. Central venous catheter-related thrombosis (CVCT) is a major complication that can cause significant morbidity and mortality. We sought to explore the rate of CVCT in a general cancer population in Australia and to identify factors associated with increased risk of thrombosis.

Design:

This is a multi-centre retrospective cohort study.

Setting and participants:

We analysed key patient, treatment, and cancer-related factors for 317 patients with cancer and central venous catheters inserted for systemic therapy.

Main outcome measures:

Symptomatic CVCT confirmed with imaging and management of patients with CVCT.

Results:

A total of 402 cases of central line insertion were analysed. Central venous catheter-related thrombosis occurred in 24 patients (6.0%). Having a peripherally inserted central catheter (PICC; HR = 3.78, 95% CI = 1.28-11.19, P = .02) compared with an implantable port and a body mass index of ⩾25.0 kg/m2 (HR = 3.60, 95% CI = 1.31-9.85, P = .01) were independently associated with increased risk of thrombosis. Central venous catheter-related thrombosis was managed mostly with removal of the catheter (19 of 24 cases) and anticoagulation, including direct-acting oral anticoagulants in 5 patients.

Conclusions:

This work explored rates of CVCT in a general cancer population, observing increased rates in those with PICCs or increased body mass index.



中文翻译:

癌症中的中心静脉导管血栓形成:一项调查危险因素和当代管理趋势的多中心回顾性研究。

目标:

许多癌症患者需要中心静脉通路来促进化疗。中心静脉导管相关血栓形成 (CVCT) 是一种主要的并发症,可导致显着的发病率和死亡率。我们试图探索澳大利亚普通癌症人群中 CVCT 的发生率,并确定与血栓形成风险增加相关的因素。

设计:

这是一项多中心回顾性队列研究。

设置和参与者:

我们分析了 317 名癌症患者和插入中心静脉导管进行全身治疗的关键患者、治疗和癌症相关因素。

主要观察指标:

有症状的 CVCT 通过 CVCT 患者的影像学和管理得到证实。

结果:

共分析了 402 例中心线插入病例。24 名患者(6.0%)发生中心静脉导管相关血栓形成。与植入式端口相比,外周插入中心导管 (PICC; HR = 3.78, 95% CI = 1.28-11.19, P  = .02),体重指数为 25.0 kg/m 2 (HR = 3.60, 95% CI = 1.31-9.85,P  = .01)与血栓形成风险增加独立相关。中心静脉导管相关血栓形成主要通过拔除导管(24 例中的 19 例)和抗凝治疗,包括 5 例患者的直接作用口服抗凝剂。

结论:

这项工作探讨了普通癌症人群中 CVCT 的发生率,观察到 PICC 患者的发生率增加或体重指数增加。

更新日期:2020-08-31
down
wechat
bug